Drug profile · INN
ombitasvir hydrate/paritaprevir hydrate/ritonavir
VIEKIRAX INITIAL APPROVAL
ombitasvir hydrate/paritaprevir hydrate/ritonavir (VIEKIRAX INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
PMDA: approved
Patents linked 1
Pipeline programs 0
News articles 0
Drug details — ombitasvir hydrate/paritaprevir hydrate/ritonavir
- Class
- —
- Route
- —
- Patents
- 1
- Programs
- 0
- Data quality
- 0.78
Quick answer
ombitasvir hydrate/paritaprevir hydrate/ritonavir (VIEKIRAX INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
Key facts
INN ombitasvir hydrate/paritaprevir hydrate/ritonavir
Brand VIEKIRAX INITIAL APPROVAL
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Related patents
Frequently asked questions
What is ombitasvir hydrate/paritaprevir hydrate/ritonavir?
ombitasvir hydrate/paritaprevir hydrate/ritonavir (VIEKIRAX INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for ombitasvir hydrate/paritaprevir hydrate/ritonavir?
VIEKIRAX INITIAL APPROVAL is a marketed brand name for ombitasvir hydrate/paritaprevir hydrate/ritonavir. Check FDA Drugs@FDA for the current US label holder and prescribing information.